• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Effective subcutaneous C1-inhibitor for hereditary angioedema prophylaxis: The COMPACT trial

byShaidah Deghan, MSc. MDandJames Roebker
March 23, 2017
in Chronic Disease, Dermatology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. The self-administered, subcutaneous C1-inhibitor CSL830 demonstrated a dose-dependent high efficacy in the prophylactic treatment of hereditary angioedema (HAE) attacks compared to placebo.

2. CSL830 was well-tolerated and not associated with significant adverse events.

Evidence Rating Level: 1 (Excellent) 

HAE is a rare genetic disorder resulting from a deficiency (type 1) or dysfunction (type II) of C1INH. Although the characteristic attacks of skin and mucosal swelling spontaneously resolve, these episodes are disabling and potentially life-threatening. Current prophylactic treatment for acute HAE is limited to regular intravenous C1 inhibitor replacement and is therefore associated with the risks of regular venous access and indwelling catheterization. This trial examined the efficacy and safety of a subcutaneously injected, nanofiltered C1 inhibitor (CSL830) for the prevention of angioedema at two different doses. The primary end point – the number of angioedema attacks – was significantly reduced at both CSL830 40 and 60 IU/kg doses compared to placebo. Among secondary endpoints, the percentage of patients that demonstrated a response to CSL830 treatment was significantly increased and the number of times rescue medication was needed for an acute attack was significantly reduced with CSL830. The most common adverse effect with CSL830 and placebo was mild injection site reactions and no other significant adverse events were reported with CSL830. The results suggest that CSL830 may be an effective prophylactic agent for HAE to overcome the technical challenges and associated risks of current intravenous therapy.

This was a multicenter, randomized, double-blind, placebo controlled, and dose-ranging trial. A crossover design was used for the four treatment arms and high and low volume placebos were used to maintain blinding. An observation period of 14 weeks would be considered a limitation because it may have prevented assessment of potential long-term adverse effects.

Click to read the study, published today in NEJM

RELATED REPORTS

2 Minute Medicine Rewind September 2, 2024

#VisualAbstract: Donidalorsen Every 4 or 8 Weeks Led to a Lower Monthly Attack Rate Than Placebo in Patients with Hereditary Angioedema

#VisualAbstract Sebetralstat Provides Faster Symptom Relief and Reduced Severity in Hereditary Angioedema Attacks

Relevant Reading: Phase II study results of a replacement therapy for hereditary angioedema with subcutaneous C1-inhibitor concentrate

In-Depth [randomized controlled trial]: This multicenter, double-blind, dose-ranging trial randomized 90 patients to one of four treatments in a crossover design: 16-week treatment with 40IU/kg or 60IU/kg CSL830 twice-weekly followed by 16-week treatment with placebo, or placebo followed by CSL830. 79 patients completed the study. The primary end point was the time-normalized number of HAE attacks. Secondary efficacy end points included the percentage of responders to CSL830 (defined as >50% reduction in time-normalized HAE attacks versus placebo) and time-normalized number of rescue medications needed. Adverse events were monitored throughout the study period.

CSL830 resulted in a mean difference of -2.42 with 40 IU/kg (95%CI -3.38 to -1.46; p < 0.001) and -3.51 with 60 IU/kg (95%CI -4.21 to -2.81; p < 0.001) attacks per month compared to placebo. Response rates were 76% (95%CI 62 to 87) and 90% (95%CI 77 to 96) for 40 IU/kg and 60 IU/kg, respectively. The mean number of times rescue medication was needed was 1.13 (95%CI -1.44 to 3.69) for 40 IU/kg and 0.32 (95%CI -0.33 to 0.97) for 60 IU/kg, both significantly reduced compared to placebo (p < 0.001). No significant difference in adverse events was reported. The most common adverse event was injection site reactions (31% with CSL830, 24% with placebo). No viral seroconversions were observed during the trial. The trial’s observational period was 14 weeks for each treatment period which made assessment of the safety and preventative effects of long-term continuous prophylaxis with CSL830 difficult.

Image: PD

©2017 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: allergyangioedema
Previous Post

Antioxidant supplementation did not decrease risk of dementia in older asymptomatic men: The PREADViSE trial

Next Post

Reduced yet persistent incidence of vertical HIV transmission in the United States

RelatedReports

Quick Take: Functional Outcome of Intravenous Thrombolysis in Patients With Lacunar Infarcts in the WAKE-UP Trial
Weekly Rewinds

2 Minute Medicine Rewind September 2, 2024

September 2, 2024
#VisualAbstract: Donidalorsen Every 4 or 8 Weeks Led to a Lower Monthly Attack Rate Than Placebo in Patients with Hereditary Angioedema
StudyGraphics

#VisualAbstract: Donidalorsen Every 4 or 8 Weeks Led to a Lower Monthly Attack Rate Than Placebo in Patients with Hereditary Angioedema

August 13, 2024
#VisualAbstract Sebetralstat Provides Faster Symptom Relief and Reduced Severity in Hereditary Angioedema Attacks
StudyGraphics

#VisualAbstract Sebetralstat Provides Faster Symptom Relief and Reduced Severity in Hereditary Angioedema Attacks

July 31, 2024
Extensive lymphadenectomy may not increase patient survival with esophageal cancer
Chronic Disease

Benralizumab associated with histologic response in eosinophilic esophagitis

July 18, 2024
Next Post
Medicaid home-visitation program linked to reduced infant mortality

Reduced yet persistent incidence of vertical HIV transmission in the United States

Tonsillectomy may have short-term benefits in recurrent throat infection

AAP issues policy statement on children in kinship care

Spleen elastography may be effective in the diagnosis of portal hypertension

Multiple oral direct-acting antiviral regimens associated with sustained virologic response for hepatitis C virus infection

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Use of psychiatric medications may be associated with a higher risk of amyotrophic lateral sclerosis
  • Nivolumab plus ipilimumab improves survival over lenvatinib or sorafenib in liver cancer
  • Dapagliflozin may improve outcomes in patients with metabolic dysfunction-associated steatohepatitis
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.